IsoTherapeutics

Executive Summary

IsoTherapeutics is a specialized radiopharmaceutical services company based in Angleton, Texas, focusing on the development and contract manufacturing of therapeutic and diagnostic agents. The company provides end-to-end support from early-stage research and proof-of-concept studies to cGMP manufacturing for preclinical trials. Acquired by Telix Pharmaceuticals in April 2024, IsoTherapeutics strengthens Telix's U.S. manufacturing and development footprint, particularly for radiopharmaceuticals. The integration is expected to accelerate Telix's pipeline of targeted radiotherapies and diagnostics, leveraging IsoTherapeutics' established infrastructure and expertise. As a wholly owned subsidiary, IsoTherapeutics' performance is tied to Telix's broader strategic goals, including advancing key programs like TLX591 (PSMA) and TLX250-CDx (CA9) towards regulatory approvals. The company's future growth hinges on successful technology transfer, scaling of manufacturing capabilities, and pipeline progression within the Telix umbrella.

Upcoming Catalysts (preview)

• Q3 2026Progress of Telix’s lead programs (TLX591, TLX250) through clinical milestones70% success
• TBDExpansion of cGMP manufacturing capacity at the Angleton facility for commercial supply80% success
• Q4 2026New contract manufacturing agreements or collaborations leveraging IsoTherapeutics' services50% success